

Bibliografía recomendada

1. ACC/AHA practice guidelines. Management of patients with peripheral arterial disease. *Circulation*. 2006;113:1474-547.
 2. Assadian, et al. *Antithrombotic strategies in vascular surgery. Evidence and practice*. Eur J Vasc Endovasc Surg. 2005;29:516-21.
 3. Blaum A, et al. *Venous thromboembolism. Review*. BMJ. 2006;332:215-9.
 4. Carreira J, Maynar M. *Diagnóstico y terapéutica endoluminal. Radiología intervencionista*. Barcelona: Masson; 2002.
 5. Estevan J. *Guías y protocolos de patología vascular para atención primaria*. Cursos del Colegio de Médicos de Oviedo; 2000-2004.
 6. García Olmos L, Moreno R. *Actualización de patología vascular para el médico de atención primaria*. Cursos Jano. Barcelona: Doyma; 2002.
 7. Halperin J, Fuster V. *Meeting the challenge of peripheral arterial disease*. Arch Inter Med. 2003;163:877-88.
 8. Hankey G, et al. *Medical management of peripheral arterial disease*. JAMA. 2006;295:547-53.
 9. Hirsch A. *Mandate for creation of a national peripheral arterial disease public awareness program: An opportunity to improve cardiovascular health*. Vasc Endovasc Surg. 2004;38:121-9.
 10. Kagan A, et al. *Atherosclerosis of the aorta and coronary arteries in five towns*. Bull WHO. 1976;53:485-645.
 11. Kyle P, et al. *Deep venous thrombosis*. Lancet. 2005;365:1163-74.
 12. Latorre J, et al. *Pie diabético*. An Cir Card Vasc. 2006;12:12-26.
 13. Lecumberri R. *Nuevas estrategias en la prevención secundaria de la recurrencia de la tromboembolia venosa*. Med Clin. 2005;125:748-56.
 14. Marinello J, Gesto R. *Patología venosa. Guía de diagnóstico y tratamiento del capítulo español de flebología de la SEACV*. Luzán/FAES; 2003.
 15. Marinello J. *Úlceras por hipertensión venosa*. Barcelona: EDIKA MED; 2005.
 16. Medrano M, et al. *Factores de riesgo cardiovascular en la población española. Metaanálisis de estudios transversales*. Med Clin. 2005;124:606-12.
 17. Moreno R. *Estrategias diagnósticas y terapéuticas en las úlceras de las extremidades inferiores*. An Cir Card y Vasc. 2005;11:278-89.
 18. Rocha E. *Enfermedad tromboembólica venosa. Resumen y comentarios de la conferencia del ACCP*. Acción Médica; 2006.
 19. Rutherford R. *Vascular surgery*. 6th ed. Saunders; 2005.
 20. Vaquero F. *Tratado de las enfermedades vasculares periféricas*. Barcelona: Viguera; 2006.
 21. Wells P, et al. *Does this patient have deep venous thrombosis? Review*. JAMA. 2006;295:199-207.
- ### FLEBOPATÍAS
22. Agnelli G, et al. *Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis*. NEJM. 2001;345:165-9.
 23. Aguilera C, et al. *Uso de heparinas de bajo peso molecular en el embarazo*. Med Clin (Barc). 2002;118:634-5.
 24. Alós J, et al. *Efficacy and safety of sclerotherapy using polidocanol foam: a controlled clinical trial*. Eur J Vasc Endovasc Surg. 2006;31:101-7.
 25. Alpert J. *How can we improve our use of oral anticoagulants*. Am J Med. 2005;119:101-2.
 26. Anjesky D, et al. *Oral anticoagulants strategies after a first idiopathic VTE event*. Am J Med. 2005;118:625-35.
 27. Ansell. *Long-term anticoagulation: the prospect for alternative to warfarin*. Sem Vasc Surg. 2005;18:134-8.
 28. Arcelus J, et al. *Duración del tratamiento anticoagulante en pacientes con tromboembolismo venoso*. Med Clin (Barc). 2002 (Suppl 2):54-9.
 29. Aryal K, et al. *VTE complications following air travel: What's the quantitative risk? A literature review*. Eur J Vasc Endovasc Surg. 2006;31:187-99.
 30. Baldwin Z, et al. *Catheter-directed thrombolysis for DVT*. Vasc Endovasc Surg. 2004;38:1-9.
 31. Barwell J, et al. *Comparison of surgery and compression with compression alone in chronic venous ulceration (ESCHAR study)*. Lancet. 2004;363:1854-9.
 32. Bates S, et al. *Use of antithrombotic agents during pregnancy*. Chest. 2004 (Suppl);126: S627-44.
 33. Becker C. *Post mastectomy lymphedema. Long term results following microsurgical lymphode transplantation*. Ann Surg. 2006;243:313-5.
 34. Beckert S, et al. *Efficacy of topical pale sulfonated shale oil in the treatment of venous leg ulcer*. J Vasc Surg. 2006;43:94-100.
 35. Bellmunt S, et al. *¿Qué le depara al paciente el diagnóstico de trombosis venosa profunda? Estudio de factores pronósticos de mortalidad*.

síndrome postrombótico y calidad de vida. *Angiología*. 2006;58:39-49.

36. **Bergan J**. Severe chronic venous insufficiency: Primary treatment with sclerofoam. *Sem Vasc Surg*. 2005;18:49-56.

37. **Blatter W, et al**. Combined regional thrombolysis and surgical thrombectomy for treatment of ilio-femoral thrombosis. *J Vasc Surg*. 2004;40:620-6.

38. **Blomgren L, et al**. Randomized clinical trial of routine preoperative duplex imaging before varicose vein surgery. *Br J Surg*. 2005;92:688-94.

39. **Bloom J, et al**. Malignancy, prothrombotic mutations and the risk of venous thrombosis. *JAMA*. 2005;293:715-22.

40. **Bountouroglu D, et al**. US-guided foam sclerotherapy combined with sapheno-femoral ligation compared to surgical treatment of varicose vein. *Randomized trial*. *Eur J Vasc Endovasc Surg*. 2006;31:93-100.

41. **Brem H, et al**. Protocol for the successful treatment of venous ulcers. *Am J Surg*. (Suppl July 2004);188:1-8.

42. **Cairols M, et al**. Tratamiento ambulatorio de los pacientes con trombosis venosas de MM.II. Práctica habitual en un hospital de referencia. *Angiología*. 2002;54:380-9.

43. **Camblor L, et al**. Tratamiento de las úlceras vasculares crónicas con equivalentes cutáneos obtenidos mediante ingeniería tisular. *Angiología*. 2003;55:21-33.

44. **Carpentier P, et al**. Prevalence, risk factors and clinical patterns of chronic venous disorders of lower limbs. A population-based study in France. *J Vasc Surg*. 2004;40:650-60.

45. **Coleridge-Smith P, et al**. Duplex US investigations of the veins in chronic venous disease of the lower limb. *UI phlebology consensus document*. *Eur J Vasc Endovasc Surg*. 2006;31:83-92.

46. **Criqui M, et al**. Chronic venous disease in an ethnically diverse population. *The San Diego population study*. *Am J Epidemiol*. 2003;158:448-56.

47. **Cronin P, et al**. Venous covered stent. Success full of a symptomatic internal iliac arterio-venous fistula. *Cardiovasc Intervent Radiol*. 2002;25:323-5.

48. **Cushmann M, et al**. DVT and PE in two cohorts: The longitudinal investigation of thromboembolic etiology. *Am J Med*. 2004;117:19-25.

49. **Chiesa R, et al**. Chronic venous insufficiency in Italy: the 24-cities cohort study. *Eur J Vasc Endovasc Surg*. 2005;30:422-9.

50. **De la Fuente N, et al**. Cribado de neoplasia oculta en pacientes afectados de trombosis venosa profunda primaria. *Angiología*. 2002;54:76-83.

51. **Doukatis J**. Use of a clinical prediction score in patients with suspected DVT: Two steps forward, one step back ? Editorial. *Ann Intern Med*. 2005;143:140-1.

52. **Escribano J, et al**. Durability of reflux-elimination by a minimed invasive CHIVA procedure of patients with varicose veins. A 3-year prospective case study. *Eur J Vasc Endovasc Surg*. 2003;25:159-63.

53. **Esteban C, et al**. Aplicación de la estrategia CHIVA. Estudio prospectivo a 1 año. *Angiología*. 2004;56:227-35.

54. **Fiessinger N, et al**. Ximelagatran vs LMWH and warfarin for the treatment of DVT. *JAMA*. 2005;293:681-9.

55. **Gajic O, et al**. Long air travel before major surgery: A prescription for thromboembolism? *Mayo Clinic Procc*. 2005;80:728-31.

56. **Geerts W, et al**. Prevention of venous thromboembolism. *Chest*. 2004;126(Suppl):338-400.

57. **Gillet J, et al**. Superficial thrombophlebitis in non-varicose veins of lower limbs. *Phlebology Digest*. 2005;29:263-72.

58. **Gohel M, et al**. Risk factors for delayed healing and recurrence of chronic venous leg ulcers. An analysis of 1.324 legs. *Eur J Vasc Endovasc Surg*. 2005;29:74-7.

59. **Goodacre S, et al**. Variation in the diagnosis performance of D-Dimer for suspected DVT. *QJM*. 2005;98:513-27.

60. **Hartung O, et al**. Endovascular stenting in the treatment of pelvic vein congestion caused from by untcraker syndrome. *J Vasc Surg*. 2005;42:275-80.

61. **Heneghan C, et al**. Self-monitoring of oral anticoagulants: a systematic review and meta-analysis. *Lancet*. 2006;367:404-11.

62. **Henke P**. Venous thromboembolism: New perspectives. *Sem Vasc Surg*. 2005; 18, todo el número de septiembre.

63. **Hinchliffe R, et al**. A prospective randomized controlled trial of VNUS closure versus surgery for the treatment of recurrent varicose veins. *Eur J Vasc Endovasc Surg*. 2006;31:212-8.

64. **Hoppener M, et al**. New anticoagulants and thromboprophylaxis. *Br J Surg*. 2005;92:259-61.

65. **Hull R**. Revisiting the past strenghtens the presents: An evidence-based medicine approach for the diagnosis of DVT. *Ann Intern Med*. 2005;142:583-4.

66. **Hyers T.** *Heparin and other rapidly acting anticoagulants.* *Sem Vasc Surg.* 2005;18:130-3.
67. **Javier A, et al.** *Reposo en cama o deambulación precoz como tratamiento de la fase aguda de la trombosis venosa profunda.* Revisión sistemática y metaanálisis. *Med Clin (Barc).* 2004;122:641-7.
68. **Johnston J, et al.** *Cost-effectiveness of prophylactic LMWH in pregnant women with a prior history of VTE.* *Am J Med.* 2005;118:503-14.
69. **Jull A, et al.** *Pentoxifylline for the treatment of venous leg ulcers. A systematic review.* *Lancet.* 2002;359:1550-4.
70. **Jünger M, et al.** *Efficacy and tolerability of an ulcer compression stocking for therapy of chronic venous ulcer compared with a below-knee compression bandage.* *Curr Med Res Opin.* 2004;20:1613-23.
71. **Kabnick L.** *Outcome of different endovenous laser wavelengths for great saphenous ablation.* *J Vasc Surg.* 2006;43:88-93.
72. **Kahn S, et al.** *Relationship between DVT and the postthrombotic syndrome.* *Arch Intern Med.* 2004;164:17-26.
73. **Keanon C, et al.** *A randomized trial of diagnostic strategies after normal proximal vein US for suspected DVT. D-Dimer testing compared with repeated ultrasonography.* *Ann Intern Med.* 2005;142:490-6.
74. **Lambert K, et al.** *Vacuum assisted closure: A review of development and current applications.* *Eur J Vasc Endovasc Surg.* 2005;29:219-26.
75. **López C, et al.** *Patogenia de la trombosis asociada a enfermedades neoplásicas. Implicaciones terapéuticas.* *Med Clin.* 2004;122:190-6.
76. **Lozano F, et al.** *La insuficiencia venosa crónica en España. Estudio epidemiológico RELIEF.* *Angiología.* 2001;53:5-16.
77. **Marinello Roura J, et al.** *Estudio observacional prospectivo y multicéntrico del tratamiento ambulatorio de la trombosis venosa en fase aguda en el sector fémoro-poplíteo-distal.* *Angiología.* 2004;56:183-92.
78. **Martínez Brotons F.** *Nuevos fármacos anti-trombóticos.* *Med Clin (Barc).* 2002;119:742-8.
79. **Martínez Ramos D, et al.** *Úlcera de Marjolin sobre una úlcera venosa crónica. Revisión de la bibliografía y comunicación de un caso.* *Angiología.* 2006;58:63-6.
80. **Masuada E, et al.** *The effect of ultrasound-guided sclerotherapy of incompetent perforator vein on venous clinical severity and disability scores.* *J Vasc Surg.* 2005;43:551-7.
81. **Menéndez B, et al.** *Comparing self-management of oral anticoagulation therapy with clinic management. A randomized trial.* *Ann Intern Med.* 2005;142:1-10.
82. **Michaels J, et al.** *Randomised clinical trial comparing surgery with conservative treatment for uncomplicated varicose vein.* *Br J Surg.* 2006;93:175-81.
83. **Neglen P, et al.** *Endovascular surgery in the treatment of chronic primary and postthrombotic iliac vein obstruction.* *Eur J Vasc Endovasc Surg.* 2000;20:560-1.
84. **Nicolini P, et al.** *Treatment of primary varicose vein by endovenous obliteration with VNUS closure system.* *Eur J Vasc Endovasc Surg.* 2005;29:433-9.
85. **Ondega R, et al.** *The Wells rule does not adequately rule out DVT in primary care patients.* *Ann Intern Med.* 2005;143:100-7.
86. **Ost D, et al.** *Duration of anticoagulation following VTE. A meta-analysis.* *JAMA.* 2005;294:706-17.
87. **Partsch H, et al.** *Immediate mobilization in acute vein thrombosis reduces postthrombotic syndrome.* *Inter Angiol.* 2004;23:206-12.
88. **Prandoni P, et al.** *Below-knee elastic compression stockings to prevent the postthrombotic syndrome.* *Ann Intern Med.* 2004;141:249-56.
89. **Ramos M, et al.** *Búsqueda de neoplasia oculta asociada a trombosis venosa profunda idiopática.* *Angiología.* 2001;53:404-14.
90. **Ratcliffe J, et al.** *Cost-effectiveness analysis of surgery versus conservative treatment for uncomplicated varicose vein in a randomised clinical trial.* *Br J Surg.* 2006;93:182-6.
91. **Roche E.** *Proyecto organizativo: centro de actuación de heridas crónicas de las extremidades inferiores.* *Angiología.* 2005; Suppl 1;S1-24.
92. **Rodríguez A, et al.** *Recomendaciones al viajero en situaciones especiales.* *Med Clin (Barc).* 2006;126:25-33.
93. **Sarani B, et al.** *Role of optional IVC filter in surgical patients at the risk for VTE disease.* *J Am Coll Surg.* 2005;201:957-64.
94. **Schreijer A, et al.** *Activation of coagulation system during air travel: a crossover study.* *Lancet.* 2006;367:832-8.
95. **Segal J, et al.** *Outpatient therapy with LMWH for the treatment of VTE: A review of efficacy, safety and cost.* *Am J Med.* 2003;115:298-308.
96. **Simon D, et al.** *Management of venous leg ulcers.* *BMJ.* 2004;328:1358-62.

97. **Soto M, et al.** Utilidad del dímero-D en la enfermedad tromboembólica venosa. *Med Clin (Barc)*. 2005;124:749-53.
98. **Stein P, et al.** Twenty-one-year trends in the use of inferior vena cava filter. *Arch Intern Med*. 2004;164:1541-5.
99. **Teruya T, et al.** New approaches for the treatment of varicose vein. *Surg Clin North Am*. 2004;84:1397-417.
100. **Tiwai A, et al.** Management of lower limb lymphedema. *Eur J Vasc Endovasc Surg*. 2006;31:311-5.
101. **Trujillo A, et al.** Reposo en cama o deambulación precoz como tratamiento de la fase aguda de la trombosis venosa profunda. Revisión sistemática y meta-análisis. *Med Clin (Barc)*. 2004;122:641-7.
102. **Wells P, et al.** A randomized trial comparing LMWH for the outpatient treatment of DVT and PE. *Arch Intern Med*. 2005;165:733-8.
103. **Yamada N, et al.** Pulse-spray pharmacological thrombolysis for proximal DVT. *Eur J Vasc Endovasc Surg*. 2006;31:204-11.
104. **Yamaki T, et al.** Prospective evaluation of a screening protocol to exclude DVT on the basis of a combination of quantitative D-Dimer testing and pre-test clinical probability scale. *J Am Coll Surg*. 2005;201:701-9.
105. **Abbruzzese T, et al.** Statin therapy is associated with improved potency of autogenous infrainguinal bypass grafts. *J Vasc Surg*. 2004;39:1178-86.
106. **Adan D, et al.** Trends in the presentation and surgical management of acute diabetic foot. *Eur J Vasc Endovasc Surg*. 2006;31:151-6.
107. **Al-Delainy, et al.** Effect of type 2 diabetes and duration on the risk of peripheral arterial disease among me. *Am J Med*. 2004;116:236-40.
108. **Amighi J, et al.** Outcome of conservative therapy of patients with severe intermittent claudication. *Eur J Vasc Endovasc Surg*. 2004;27:254-8.
109. **Aronow WS.** Management of peripheral arterial disease. *Cardiol Rev*. 2005;13:61-8.
110. **Banegas J, et al.** La mortalidad atribuible al tabaquismo comienza a descender en España. *Med Clin*. 2005;124:769-71.
111. **Jensen S, et al.** The association between smoking and the prevalence of peripheral arterial disease. *Vasc Med*. 2005;10:257-63.
112. **Barandon L, et al.** The therapy for chronic PAD. What role for the vascular surgeon? *Ann Vasc Surg*. 2004;18:758-65.
113. **Baxter T.** Non aortic aneurysms: diagnosis and treatment in the endovascular era. *Sem Vasc Surg*. 2005;18: número de diciembre (completo).
114. **Beck J, et al.** Assessment of disease impact in patient with IC: discrepancy between health status and quality of life. *J Vasc Surg*. 2005;41: 443-50.
115. **Becquemin J.** EVAR: New developments and extended applicability. *Eur J Vasc Endovasc Surg*. 2004;27:453-5.
116. **Belch J, et al.** Critical issues in PAD. Detection and management. *Arch Intern Med*. 2003; 163: 884-92.
117. **Berger J, et al.** Aspirin for the primary prevention of cardiovascular events in women and men. A six meta-analysis of randomised controlled trials. *JAMA*. 2006;295:306-13.
118. **Bhatt D, et al.** International prevalence recognition and treatment of cardiovascular risk factors in outpatients with atherosclerosis. *JAMA*. 2006;295:180-9.
119. **Börner G, et al.** Percutaneous AAA repair: Is it safe? *J Endovasc Ther*. 2004;11:621-6.
120. **Bossiers M, et al.** Excimer laser assisted angioplasty for claudication intermittent. Results of the LACI Belgium study. *Eur J Vasc Endovasc Surg*. 2005;29:613-9.
121. **Bossier M, et al.** Heparin-bonded expanded PTFE vascular graft for femoropopliteal and femorocrural bypass grafts. *J Vasc Surg*. 2006; 43:313-8.
122. **Brott T, et al.** Carotid revascularization for prevention of stroke: CEA and carotid artery stenting. *Mayo Clin Proc*. 2004;79:1197-208.
123. **Brunckwall J, et al.** The influence of endovascular technique on our surgical practice. A 10 years view. *J Endovasc Ther*. 2004;11 (Suppl II):5-9.
124. **CAESAR trial collaborators.** Comparison of surveillance versus endografting for small aneurysms repair. Study design and progress. *Eur J Vasc Endovasc Surg*. 2005;30:245-51.
125. **Caglayan E, et al.** Phosphodiesterase type 5 inhibition is a novel therapeutic option in Raynaud disease. *Arch Intern Med*. 2006;166: 231-3.
126. **CARESS stenting Committee.** Carotid revascularization using EA or stenting system. Phase I clinical trial. 1 year results. *J Vasc Surg*. 2005; 42:213-9.
127. **Casey K, et al.** Medical management of intermittent claudication. *Vasc Endovasc Surg*. 2004; 38:391-9.
128. **Cassar K, et al.** Randomized clinical trial of the antiplatelet effects of aspirin clopidogrel com-

129. **Clagett G, et al.** Antithrombotic therapy in peripheral arterial occlusive disease. *Chest*. 2004; 126(Suppl):609-26.
130. **Cocca A, et al.** Tratamiento y control del riesgo cardiovascular en atención primaria en España. Estudio PREVENCAT. *Med Clin (Barc)*. 2006;126: 201-5.
131. **Collins T, et al.** Ethnicity and peripheral arterial disease. *Mayo Clin Procc.* 2005;80:48-51.
132. **CTT.** Efficacy and safety of cholesterol-lowering treatment, prospective meta-analysis of dates from 90,056 participants in 14 randomized trials of statins. *Lancet*. 2005;366:1267-78.
133. **Chaikoff E.** Endovascular surgery: a potpourri of new developments. *Sem Vasc Surg*. 2006; 19: número de junio completo.
134. **Daemens K, et al.** Hemoban stent-grafts in the treatment of femoropopliteal occlusive disease. *J Cardiovasc Surg*. 2005;46:25-31.
135. **Devalic K, et al.** Remote superficial femoral endarterectomy: long-term results. *Eur J Vasc Endovasc Surg*. 2006;31:262-5.
136. **Delis K, et al.** Enhancing foot skin blood flux in PAD using intermittent pneumatic compression: controlled study on claudicants and grafted arterioplasts. *World J Surg*. 2002;26:861-8.
137. **Dillaron E, et al.** Improving aneurysms-related outcomes. Nationwide benefits of endovascular repair. *J Vasc Surg*. 2006;43:446-52.
138. **Drury D, et al.** Systematic review of recent evidence for the safety and efficacy of elective endovascular repair in the management of infrarenal AAA. *Br J Surg*. 2005;92:937-46.
139. **Durazzo A, et al.** Reduction in cardiovascular events after vascular surgery with atorvastatin: A randomized trial. *J Vasc Surg*. 2004;39:967-75.
140. **Ehrenstein M, et al.** Statins for atherosclerosis ¿As good as it gets? *NEJM*. 2005;352:73-75.
141. **Estevan J, Maynar M.** Terapéutica percutánea ¿una nueva especialidad? *Med Clin*. 1996; 106: 294-7.
142. **Gjonnoess E, et al.** Gadolinium –enhanced MRA color Duplex and digital subtraction angiography of the lower limbs arteries from the aorta to the tibioperoneal trunk in patients with CI. *Eur J Vasc Endovasc Surg*. 2006;31:53-58.
143. **Goessens B, et al.** Screening for asymptomatic cardiovascular disease with noninvasive imaging in patients at high-risk and low-risk according to the European guidelines on cardiovascular disease prevention: the SMART study. *J Vasc Surg*. 2006;43:525-32.
144. **Goldberg A, et al.** Efficacy and safety of ezetimibe coadministered with simvastatin in patient with primary hipercolesterolemia. *Mayo Clin Procc.* 2004;79:620-9.
145. **Goldstein L.** Advances in primary stroke prevention. *Stroke*. 2006;37:317-9.
146. **Golledge J, et al.** The small AAA. *Eur J Vasc Endovasc Surg*. 2005; 31: 237-8.
147. **González M, et al.** Estudio de la frecuencia por la enfermedad vascular en atención primaria. *Angiología*. 2002;54:118-26.
148. **Goodney P, et al.** Current status of carotid artery stenting. *J Vasc Surg*. 2006;43:406-11.
149. **Hackman D.** Cardiovascular risk prevention in peripheral arterial disease. *J Vasc Surg*. 2005;41:1070 -3.
150. **Hartung O.** Efficacy of Hemoban in the treatment of superficial femoral artery lesions in patients with acute or critical ischaemia. A comparative study with claudicants. *Eur J Vasc Endovasc Surg*. 2005;30:300-6.
151. **HPS collaborative group.** Cost-effectiveness of simvastatin in people of different levels of vascular disease risk. Analysis of a randomised trial in 20,536 individuals. *Lancet*. 2005;365:1779-85.
152. **Hennekens C, et al.** Additive benefits of pravastatin and aspirin to decrease risk of cardiovascular disease. Randomized and observational comparisons of secondary prevention trial and their meta-analysis. *Arch Intern Med*. 2004;164:40-4.
153. **Jönsson B, et al.** Automatic ankle pressure measurement using PPG in a ankle-brachial pressure index determination. *Eur J Vasc Endovasc Surg*. 2005;30:395-401.
154. **Kennedy M, et al.** Risk factors for declining ankle-brachial index in man and woman 65 year older. The CVHS study. *Arch Intern Med*. 2005; 165:1896-902.
155. **Kertai M, et al.** Association between long-term statin use and mortality after successful AAA surgery. *Am J Med*. 2004;116:96-103.
156. **Knigh J, et al.** Multicenter study to assess the feasibility of new covered stent and delivery system in combination with remote SFA endarterectomy. *Eur J Vasc Endovasc Surg*. 2005;29:287-94.
157. **Krupski W, Rutherford R.** Update on open repair of AAA: The challenges for endovascular repair. *J Am Coll Surg*. 2004;199:946-60.
158. **Laird J, et al.** Cryoplasty for the treatment of femoropopliteal arterial disease. Extended follow-

- up results. *J Endovasc Ther.* 2006;13(Suppl II):52-9.
159. **Laird J, et al.** *Limb salvage following laser-assisted angioplasty in critical limb ischaemia Results of the LACI multicenter trial.* *J Endovasc Ther.* 2006;13:1-13.
160. *Lifeline registry of EVAR publication committee of endovascular registry of endovascular aneurysm repair: Long term primary outcome measures.* *J Vasc Surg.* 2005;42:1-10.
161. **Long J, et al.** *Correlation between ankle-brachial index, symptoms and health-related quality of life in patients with PAD.* *J Vasc Surg.* 2004;39:723-8.
162. **Marrewijk C, et al.** *Risk-adjusted outcome analysis of endovascular AAA repair in a large population. How do stent-grafts compare?* *J Endovasc Ther.* 2005;12:417-29.
163. **Martin A, et al.** *Frecuentación por patología vascular en atención primaria.* *Angiología.* 2005;57:237-42.
164. **Martín Zurro A.** *Compartir y coordinar la atención a los pacientes entre el hospital y la atención primaria. Algunas propuestas prácticas.* *Atención Primaria.* 2000;26:74-75.
165. **Maynar M, et al.** *Bifurcated endoprosthesis for treatment of aortoiliac occlusive lesions.* *J Endovasc Ther.* 2005;15:22-7.
166. **McGræe M, et al.** *Physical performance in PAD: a shower rate of decline in patients who walk more.* *Ann Intern Med.* 2006;144:10-20.
167. **Metha T, et al.** *Assessing the validity and responsiveness of disease specific quality of life instruments in intermittent claudication.* *Eur J Vasc Endovasc Surg.* 2006;31:46-52.
168. **Michaels J.** *The future of endovascular aneurysm repair.* *Eur J Vasc Endovasc Surg.* 2005;30:115-8.
169. **Michaels J, et al.** *Cost-effectiveness of endovascular AAA repair.* *Br J Surg.* 2005;92:960-7.
170. **Min I, et al.** *Vitamin E in the primary prevention of cardiovascular disease and cancer. The women's health study. A randomised controlled trial.* *JAMA.* 2005;294:56-65.
171. **Moler E.** *Peripheral arterial disease. Identifications and implications.* *Arch Intern Med.* 2003;163:2306-14.
172. **Mostaza J, et al.** *Índice tobillo brazo y riesgo vascular.* *Med Clin (Barc).* 2003;121:62-73.
173. **Muralito J, et al.** *The ankle brachial index in the elderly and risk of stroke, coronary disease and death. The Framingham study.* *Arch Intern Med.* 2003;163:1939-42.
174. **Nio D, et al.** *Robot-assisted laparoscopic aortobifemoral bypass for aortoiliac occlusive disease. Early clinical experience.* *Eur J Vasc Endovasc Surg.* 2005;29:586-90.
175. **Norman P, et al.** *Infrarenal aortic diameter predicts all-cause of mortality.* *Arterioscl Thromb Vasc Biol.* 2004;24:1278-82.
176. **Ong H.** *The statin studies: from targeting hypercholesterolemia to targeting the high risk patient.* *QJM.* 2005;98:599-614.
177. **PAD antiplatelet consensus group.** *Eur J Vasc Endovasc Surg.* 2003;26:1-16.
178. **Páramo J, et al.** *Fibrinógeno: vieja proteína hemostática con nueva función. Marcador no invasivo de arteriosclerosis.* *Med Clin.* 2005;124:790-4.
179. **Parodi J.** *Long term outcome after aortic endovascular repair. The Buenos Aires experience.* *Sem Vasc Surg.* 2003;16:113-22.
180. **Pasupathy S, et al.** *Effects of warm-up on exercise capacity, platelet activation and platelet-leucocyte aggregation in patients with claudication.* *Br J Surg* 2005;92:50-5.
181. **Patel S, et al.** *The limitations of magnetic resonance angiography in the diagnosis of renal artery stenosis.* *J Vasc Surg.* 2005;41:462-8.
182. **Pignone M, et al.** *Aspirin, statins or both drug for the primary prevention of coronary hearth disease events in men: A cost-utility analysis.* *Ann Intern Med.* 2006;144:326-37.
183. **Pintó X.** *Las estatinas, los hábitos de vida y el tratamiento de la hipercolesterolemia; los tiempos cambian y los criterios también.* *Med Clin (Barc).* 2006;126:217-9.
184. **Qureshi A.** *Ten years of advances in neurovascular procedures.* *J Endovasc Ther.* 2004;11(Suppl II):1-4.
- 184 bis. **Rabasseda X.** *Pentoxifilina en las arteriopatías oclusivas periféricas. Eficacia terapéutica y su valoración coste-beneficio.* Barcelona: Prous Science; 1997.
185. **Raines J, et al.** *Ankle/brachial index in the primary care setting.* *Vasc Endovasc Surg.* 2004;38:131-6.
186. **Ramaswami G, et al.** *Rapid foot and calf compression increase walking distance in patients with IC. Results of a randomized study.* *J Vasc Surg.* 2005;41:794-801
187. **Rehring T, et al.** *Atherosclerotic risk factors control in patients with PAD.* *J Vasc Surg.* 2005;41:816-22.
188. **Resnick H, et al.** *Relationship of high and low ankle/brachial index to all cause and cardiovascu-*

- lar disease mortality. The strong hearth study. *Circulation*. 2004;109:733-9.
189. **Ridker P, et al.** A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. *NEJM*. 2005;352:1293-304.
190. **Rondoni N, et al.** Assessing the risk-benefit profile before recommending aspirin for the primary prevention of cardiovascular risk. *Am J Med*. 2004;117:528-30.
191. **Sang P, et al.** New technologies meeting old professional boundaries: the emergence of carotid artery stenting. *J Am Coll Surg*. 2005;200:854-860.
192. **Schleinitz M, et al.** Clopidogrel versus aspirin for secondary prophylaxis of vascular events: A cost-effectiveness analysis. *Am J Med*. 2004;116:797-806.
193. **Schillinger M, et al.** Statin therapy improves cardiovascular outcome of patients with PAD. *Eur Hearth J*. 2004;25:742-8.
194. **Seiner T, et al.** PAD: comparison of colour duplex US and contrast enhanced MR angiography for diagnosis. *Radiology*. 2005;235:699-708.
195. **Sherif C, et al.** Neurological outcome of conservative versus endovascular treatment of patients with asymptomatic high grade carotid artery stenosis. *J Endovasc Ther*. 2005;12:145-55.
196. **Sobeti S, et al.** Primary potency of long segment self expanding intimal stents in the femoropopliteal arteries. *J Endovasc Ther*. 2005;12:6-12.
197. **Sofi F, et al.** Thrombophilic risk factors for asymptomatic PAD. *J Vasc Surg*. 2005;41:255-61.
198. **Stames B.** Totally percutaneous AAA repair. Experience and prudence. *J Vasc Surg*. 2006;43:270-6.
199. **Stein R.** Limitation of the resting ankle/brachial index in symptomatic patients with IC. *Vasc Med*. 2006;11:29-35.
200. **Treesak C, et al.** Cost-effectiveness of exercise training to improve claudication symptoms in patients with PAD. *Vasc Med*. 2004;9:279-85.
201. **US preventive task force.** Screening for AAA. Recommendations statement. *Ann Intern Med*. 2005;142:198-202.
202. **Vaines T, et al.** Secondary prevention of atherosclerosis through chlamydia pneumoniae eradication (SPACE trial). *Eur J Vasc Endovasc Surg*. 2005;29:403-11.
203. **Valentine R, et al.** Family history is a major determinant of subclinical PAD in young patients. *J Vasc Surg*. 2004;39:351-6.
204. **Veith F.** Metamorphosis of vascular surgeon to endovascular specialist: must vascular surgery have and independent board and can we get there? *J Endovasc Ther*. 2005;12:269-73.
205. **Verhoeven E, et al.** Local anesthesia for endovascular AAA repair. *J Vasc Surg*. 2005;42:402-9.
206. **Vicente Y, et al.** Prevalencia de un índice tobillo/brazo patológico según el riesgo cardiovascular calculado mediante la función de Framingham. *Med Clin (Barc)*. 2005;124:641-4.
207. **Vorchheimer D, et al.** Platelets in atherothrombosis. *Mayo Clin Proc*. 2006;81:59-68.
208. **Wang J, et al.** Effects of exercise training and deconditioning on platelet aggregation induced by alternating shear stress in men. *Ather Thromb Vasc Biol*. 2005;25:454-60.
209. **Warren C, et al.** Patterns of global tobacco use in young people and implications for future chronic disease burden in adults. *Lancet*. 2006;367:749-53.
210. **Weiss J, et al.** Review of prevalence and outcome of vascular disease in patient with diabetes mellitus. *Eur J Vasc Endovasc Surg*. 2006;31:143-50.
211. **Wiesinger B, et al.** PTFE covered self expanding nitinol stent for the treatment of severe iliac and femoral artery stenosis and occlusions. *J Endovasc Ther*. 2005;12:240-6.
212. **Willigendael E, et al.** Smoking and the potency of lower extremity bypass grafts. A meta-analysis. *J Vasc Surg*. 2005;42:67-74.
213. **Willigendael E, et al.** PAD: public and patient awareness in the Netherlands. *Eur J Vasc Endovasc Surg*. 2004;27:622-8.
214. **Wyatt M.** Registries versus trials for the evaluation of the endovascular treatment of AAA. *Eur J Vasc Endovasc Surg*. 2005;29:560-2.
215. **Zhon W, et al.** Carotid artery aneurysms: evolution of management over two decades. *J Vasc Surg*. 2006;43: 493-6.